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Title: Effectiveness of nitric oxide agents in preventing the early onset of pre-eclampsia and 
possible modification of metabolic factors in high-risk pregnancies: a systematic review 
protocol 
ABSTRACT 
Objectives: To determine the effectiveness of nitric oxide agents in modifying the metabolic 
factors of pre-eclampsia and its effectiveness in preventing the onset of pre-eclampsia in 
high-risk pregnancies. 
Introduction: Pre-eclampsia is a major cause of maternal death during the prenatal and 
neonatal periods. Nitric oxide is a vasodilator and platelet aggregation inhibitor responsible 
for the vascular adaptation of the placenta. Although various studies have established that 
nitric oxide is effective in preventing complications from pre-eclampsia, there is limited 
evidence to show that administering nitric oxide agents to the high-risk women before 20 
weeks’ gestation will prevent the onset of pre-eclampsia. 
Inclusion criteria: This review will consider randomized controlled trials that compare nitric 
oxide donors and precursors with a placebo or no intervention on pregnant women (18 to 44 
years) with ≤ 20-week gestational age that are at high risk of pre-eclampsia. The primary 
outcome of interest will be the onset of pre-eclampsia. Secondary outcomes include increased 
systolic and diastolic blood pressure, elevated asymmetric dimethylarginine levels, decreased 
endothelial nitric oxide synthase activity, reduced maternal placental vasculature, and 
abnormal Doppler ultrasound waveforms. 
Methods: Data sources will be drawn up from MEDLINE, CINAHL, ProQuest (Health and 
Medicine) and Web of Science from inception till current date. No language restrictions will 
be applied in the search strategy. Selected studies will be assessed against the JBI critical 
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appraisal checklist, and the certainty of evidence and strength of recommendations from 
findings will also be ascertained. 
Systematic review registration number: CRD42018099298 
Keywords: Asymmetric dimethylarginine; high-risk pregnancy; nitric oxide; placental growth 
factor; pre-eclampsia 
JBI Evid Synth 2020;18(?):1-8 
INTRODUCTION 
Pre-eclampsia is a pregnancy-specific condition which affects about 8% of pregnancies.1 It is 
the major cause of fetal growth restriction and pre-term birth, which results in infants who are 
small for gestational age, with increased risk of chronic ill health due to delayed organ 
development.2 Other affects include the subsequent financial burdens on health systems both 
in developed and less-developed nations.3 Studies have reported predictive factors for pre-
eclampsia as primigravida pregnancy, family history of hypertension and pre-eclampsia, 
diabetes, renal disease, body-mass index (BMI) above 30 kg/m², hormone imbalance, 
autoimmune disorders such as systemic lupus erythematosus or antiphospholipid syndrome, 
multiple birth pregnancy, pregnancy interval greater than 10 years, and pregnancy at 40 years 
and over.4,5 
Serum concentrations of the proangiogenic maternal placental growth factor (PlGF) have 
been reported to decrease in the blood five weeks before a diagnosis of pre-eclampsia.2,5 
Alternatively, the antiangiogenic soluble fms-like tyrosine kinase-1 (sFLT-1) known as 
vascular endothelial growth factor receptor-1 increases with respect to decreased PlGF.2 The 
circulating anti-angiogenic protein antagonizes PlGF, which plays a major role in the 
pathogenesis of pre-eclampsia.6  
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Dastur and Tank7 earlier hypothesized that there is a likelihood of the disease already 
progressing when biomarkers become visible, and measures taken at this stage may be 
inclined towards preventing the outcomes rather than the onset of the syndrome. Likewise, a 
study by Zeisler et al.8 revealed that there is elevated sFLT-1/PlGF in pregnant women before 
clinical diagnosis. Kahhale et al.9 further suggested that biomarkers such as circulating PlGF, 
sFLT-1, and soluble endothelin and pregnancy-associated plasma protein-A in maternal 
blood differ significantly before 20 weeks’ gestation, which makes it possible to predict pre-
eclampsia. Therefore, researchers recommend managing clinical conditions that increase the 
risk of pre-eclampsia before 20 weeks.5 
Bartsch et al.10 suggested that nulliparity is a common risk factor associated with pre-
eclampsia, followed by BMI >30 kg/m², and prior pre-eclampsia. A relationship between 
nulliparity, Doppler indices, levels of circulating antiangiogenic protein sFLT-1, and 
placental growth factor PlGF in pre-eclampsia has been well-established. 6 Nulliparous 
pregnancies have higher circulating sFLT-1 levels and sFLT-1/PlGF ratios than multiparous 
pregnancies; and this increase/decrease in circulating angiogenic proteins is associated with 
pre-eclampsia.6 Although the first-trimester uterine artery Doppler ultrasound is reported to 
have a low sensitivity for predicting the early onset of pre-eclampsia,11 Myatt et al.12 
suggested that a combination of biomarkers, clinical risk factors, and Doppler ultrasound in 
the second trimester may be more accurate in predicting pre-eclampsia. This multiple 
approach may not be applicable in clinical practice due to the expensive nature of the tests; 
nevertheless, many researchers hold the view that a high uterine artery resistive index is 
proportional to poor vascular function, which signifies an elevation in sFLT-1.13 Thus, a 
combination of these biomarkers could serve as possible predictors of pre-eclampsia. 
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Owing to the poor knowledge of its pathophysiology, preventive measures of pre-eclampsia 
are based on established links between reduced placental perfusion due to impaired 
trophoblast differentiation and invasion of the spiral arteries that results in oxidative stress 
and thrombophilia from an increased inflammatory response.14 Proposed interventions are 
intended to minimize endothelial dysfunction and oxidative stress within the maternal blood 
vessels, which causes vasoconstriction, platelet activation, thrombosis, and reduced blood 
supply to the placenta and maternal organs.2,14 Studies on low-dose aspirin, low molecular 
weight heparin, calcium, vitamins and nutritional supplementation, antioxidants, magnesium, 
lifestyle modification, and physical activity show potential benefits in preventing the onset of 
pre-eclampsia and its complications.4 However, further research is needed to determine their 
effectiveness and safety.15 The benefits of low-dose aspirin for the prophylaxis of 
hypertension has been a point of contention in recent studies.16,17  
Nitric oxide is synthesized by a Ca2+ dependent endothelial nitric oxide synthase (eNOS) 
from molecular oxygen and nitrogen from L-arginine.18 Nitric oxide diffuses into adjacent 
vascular smooth muscle cells after its synthesis where it increases the second messenger, 
cyclic guanosine monophosphate, which mediates its effects in the endothelial cells.9,18 
Though there are no recorded teratogenic effects in human, the clinical use of nitric oxide 
(NO) agents such as glyceryl trinitrate and isosorbide mononitrate are often limited to the 
prophylaxis of angina.19 Their mechanism of action and therapeutic application in ischemia 
provides a basis for research into NO agents for the regulation of blood flow along the 
placenta. The role of NO in the pathogenesis of pre-eclampsia is linked to its ability to 
mediate the functions of the endothelium, such as vasodilatation and inhibition of platelet 
aggregation, which is essential for the vascular adaptation of the placenta and maternal 
organs in pregnancy,20 and regulation of blood capillary flow.9,18  
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After conception, epithelial trophoblast is generated on the lining of the placenta, which 
facilitates the attachment of the fetus to the uterine wall, and decidualization of the 
endometrium and myometrium.21 To promote the adaption of the maternal uterine blood 
vessels, the endovascular trophoblasts also invade the spiral artery, which widens its 
diameter, thereby minimizing resistance to blood flow and increased placental perfusion.22 
Invasion of the endovascular trophoblast occurs in two waves: the first is the invasion of the 
decidual segments of spiral arteries between eight and 10 weeks’ gestation; and the second 
with the myometrial segments between 16 and 18 weeks’ gestation.22 Trophoblast invasion is 
associated with the flow of oxygenated maternal blood through the placenta; therefore, 
partially modified vessels cause severe damage from oxidative stress and thrombophilia.21,23 
It has been reported that placental oxygenation from trophoblast invasion and transformation 
of blood vessels is dependent on the oxygen tension and PlGF expression in the placenta.21,24 
It is now well established that the expression of antiangiogenic factors and invasion of the 
myometrium by the trophoblast during placentation would be complete by 18 weeks’ 
gestation.21,22 One possible implication of this is that NO agents may be more beneficial for 
the prophylaxis of pre-eclampsia if administered before 20 weeks’ gestation. Furthermore, a 
relationship between increased levels of homocysteine, ADMA, PlGF, and sFLT-1 before 16 
weeks’ gestation and early prediction of pre-eclampsia have also been proposed.13,24 This 
could be due to the inhibition of eNOS and possible decrease in NO. 
Although preventive interventions that rely on the metabolic progression of the disease look 
promising, the evidence base is unclear for NO, thus requiring incorporation of further 
analysis of research into existing treatment protocols for pre-eclampsia. In addition, a study 
by Bartsch et al.10 shows that clinical risk factors of pre-eclampsia can be diagnosed before 
16 weeks’ gestation. This indicates the potential for NO agents to modify these risk factors, 
thereby signifying a cost-effective preventive measure when administered early enough. 
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In a previous review by Meher and Duley,25 the NO agent L-arginine was found to show 
potential benefit in the prophylaxis of pre-eclampsia; however, this study is statistically 
insignificant due to insufficient trials at that time. Notwithstanding, studies that have not yet 
been synthesized together and meet the proposed review's inclusion criteria have been 
identified (Nnate DA, 2018, unpublished data). 26 In addition, the study by Meher and 
Duley,25 also evaluated the effectiveness of NO on the complications of pre-eclampsia. 
However, there is evidence suggesting that NO intervention may be less effective when pre-
eclampsia has been diagnosed.21,22,24 This implies that the administration of NO at this stage 
in high-risk pregnancies increases the chances of maternal and perinatal morbidity and 
mortality. This study will aim to investigate the effectiveness of NO agents in preventing the 
early onset of pre-eclampsia. A preliminary search was conducted in PROSPERO, Cochrane 
Database, CINAHL, MEDLINE, Google Scholar, and Web of Science, and no existing or in-
progress systematic reviews on the topic was identified. 
REVIEW QUESTION 
Is there evidence that NO agents can prevent the early onset of pre-eclampsia when 
administered before 20 weeks’ gestation by modifying metabolic precursors such as elevated 




This review will consider studies with participants aged 18 to 44 years with ≤ 20-week 
gestational age at study entry with at least one risk factor from a previous pregnancy (history 
of pre-eclampsia, eclampsia, intrauterine growth restriction, placental abruption, or stillbirth) 
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or from current pregnancy (nulliparity or primigravidae, age > 40 years, BMI > 30 kg/m², 
gestational hypertension, chronic hypertension, pre-pregnancy type I or II diabetes mellitus, 
chronic kidney disease, or autoimmune diseases such as systemic lupus erythematosus, and 
antiphospholipid antibody syndrome), family history of pre-eclampsia, multiple pregnancy, 
or pregnancy interval >10 years. Either one or a combination of any of these risk factors has 
been recommended to identify women who are at high-risk of developing pre-eclampsia.4,10 
Studies on women with existing pre-eclampsia will be excluded. 
Interventions 
This study will consider research examining any molecule that mediates the effects of NO in 
the body, such as nitrate, NO donors (nitroglycerin, also known as glyceryl trinitrate, 
pentaerythritol tetranitrate, isosorbide mononitrate, isosorbide dinitrate, S-nitroso glutathione 
and sodium nitroprusside), and NO precursors (L-arginine, L-citrulline). The study will also 
consider interventions administered within the second trimester and before 20 weeks’ 
gestation. While a specific dosage will not be considered, the intervention must conform with 
the pharmaceutical reference guideline associated with a study setting such as the National 
Institute for Health and Care Excellence (NICE) British National Formulary27 (UK) and 
Prescribers’ Digital Reference (PDR) Drug Information28 (US). 
Comparator 
The proposed systematic review will consider studies that compared NO with placebo or no 
intervention. Studies combining NO alongside other interventions will not be considered to 
ensure that the observed effects are exclusively a result of NO. 
Outcomes 
The primary outcome will be the incidence of pre-eclampsia. This review will likewise 
consider secondary outcomes such as: 
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i) increased systolic blood pressure ≥140 mm Hg and diastolic blood pressure ≥90 mm Hg; 
ii) elevated asymmetric dimethylarginine (ADMA) levels and endothelial nitric oxide 
synthase (eNOS) activity, measured by arginine/ADMA ratio (A ratio <1 will signify 
impaired eNOS activity); 
iii) significant changes in placental vascular function from decreased level of pregnancy-
associated plasma protein-A and PlGF measured by sFLT-1/PlGF ratio (sFlt-1/PlGF 
ratio >38 represents a clinical onset of pre-eclampsia)8;  
iv) abnormal uterine artery (UtA) and middle cerebral arteries (MCA) Doppler ultrasound 
waveforms, such as pulsatility index (PI) and resistive index (RI), mean arterial 
pressure, systolic/diastolic ratio, peak systolic velocity, end-diastolic velocity, presence 
of diastolic notching, and cerebroplacental ratio (ratio of MCA PI and UtA PI). The 
cut-off values for abnormal second trimester Doppler ultrasound waveforms of the UtA 
and MCA were in accordance with the International Society of Ultrasound in Obstetrics 
and Gynecology and the Fetal Medicine Foundation. Abnormal waveforms will be 
described as RI > 95th percentile, PI > 95th percentile (not within the 50th percentile), 
presence of bilateral notch, MCA PI < 5th percentile, and absent or reverse end-
diastolic velocity. Mean systolic/diastolic ratio ≥ 2.7 (average of right and left uterine 
arteries) will be considered abnormal.29 A cerebroplacental ratio value < 1 will be 
regarded as abnormal.30  
Any reported side effects of NO agents will also be analyzed. Where studies report the early 
onset of pre-eclampsia along with other outcomes not stated within our inclusion criteria, 
then only the incidence of pre-eclampsia will be considered for analysis. 
Types of studies 
This review will consider published randomized control trials that investigate the use of NO 
agents to prevent the onset of pre-eclampsia. The authors decision to include only RCTs for 
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the systematic review is aimed at selecting quality experimental studies in order to maintain a 
high level of evidence base in line with JBI levels of evidence.31 This is to ensure that 
included studies meet the ethical requirements for human participants and adhere to the 
consolidated standards of reporting trials (CONSORT) guidelines as recommended in the JBI 
critical appraisal checklist for randomized control trials.32 
METHODS  
The protocol is developed in accordance with JBI methodology for systematic reviews of 
effectiveness evidence.32 
Search strategy 
An initial search on the Cochrane Database was undertaken to identify articles on the topic 
(Nnate DA, 2018, unpublished data).26 The second step will involve the development of 
search strings from an analysis of text words from the title, abstract, and index terms used to 
describe the articles. This strategy will then be utilized for a full search on MEDLINE from 
inception (Appendix I) and then adapted for each included information source. The reference 
lists of included studies will be searched as will reviews and meta-analysis for relevant 
studies. Titles and abstracts of studies not available in English will be first translated using 
Google Translate to determine their eligibility. Thereafter, the authors and journal publishers 
of relevant studies not published in English will be contacted regarding the availability of an 
English version. However, where none is available, the study will be excluded. 
Information sources 
Data sources will include MEDLINE via Ovid; CINAHL via EBSCOhost; ProQuest (Health 
and Medicine) and Web of Science via Clarivate Analytics. Relevant studies will also be 
extracted from Google Scholar, NICE Evidence search, Health Management Information 
Consortium, Cochrane CENTRAL, and National Institute for Health Research (NIHR) 
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journal library. Manual searches will also be carried out on ClinicalTrials.gov and journals 
related to obstetrics and gynecology. The authors of unpublished studies found in any of the 
databases that reported similar outcomes of interest will be contacted to ensure the reviewers 
have access to the most salient literature. Furthermore, characteristics and results of 
unpublished studies will be recorded within the appendix in case of further updates to the 
systematic review. 
Study selection 
Identified citations will be collated and uploaded into EndNote vX9 (Clarivate Analytics, PA, 
USA). Duplicates will be removed to avoid overestimation of treatment effect. Titles and 
abstracts of all identified studies from the searched databases will be screened independently 
by two reviewers against the inclusion and exclusion criteria. The citation details of 
potentially relevant studies will be entered into the JBI System for the Unified Management, 
Assessment and Review of Information (JBI SUMARI; JBI, Adelaide, Australia). Any 
conflict encountered during the initial screening of titles and abstracts will be resolved via 
discussion between the two authors or through a third reviewer who will perform an 
additional independent evaluation. The result of each stage of the search will be recorded 
using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 
flow diagram with the following details: number of studies found, number of duplicates 
removed, and excluded studies;33 and reasons for exclusion provided in an appendix in the 
final systematic review report.  
Assessment of methodological quality 
The quality of each study will be independently assessed prior to inclusion by two reviewers 
using the JBI critical appraisal checklist for RCTs.32 Where studies are rated “no” or 
“unclear,” an agreement will be reached between the authors or with a third reviewer, who 
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will perform an additional independent evaluation. However, studies that record a "no" to 
“randomization of participants to treatment groups” will be excluded. Where quality of study 
is unclear, corresponding authors will be contacted for more details. 
Data extraction 
Characteristics of included studies will be recorded independently by both reviewers using a 
standard JBI quantitative data extraction tool.32 Extracted data will include: study 
characteristics (name of authors, year of publication, country of origin, objectives, context, 
description of interventions and study design); participants characteristics (number of 
participants, BMI, gestational age, and risk factors at enrolment); and study results based on 
outcomes. 
Data synthesis 
Studies will, where possible, be pooled with statistical meta-analysis using JBI SUMARI. 
Effect sizes will be expressed as risk ratios (for dichotomous data) or weighted final post-
intervention mean differences (for continuous data) and their 95% confidence intervals 
calculated for analysis. The treatment effect across subgroups of the various nitric oxide 
agents will be determined; and heterogeneity will be measured by checking if the confidence 
intervals overlap using the standard Q and I² statistic. The pooled effect and variabilities 
among studies will be analyzed to prevent the likelihood of drawing conclusions from 
variables that cannot be attributed to chance, and the results represented as forest plots. 
Statistical analyses will be performed using random effects model.33 A sensitivity analysis 
will also be conducted to ascertain how likely the results are to change from the inclusion of 
studies of lower methodological quality in meta-analyses. In addition, a funnel plot will be 
generated using JBI SUMARI to assess publication bias if there are 10 or more studies 




Assessing certainty in the findings 
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
approach for grading the certainty of evidence will be followed,34, 35 and a Summary of 
Findings will be created using the GRADEPro guideline development tool (McMaster 
University, ON, Canada). The Summary of Findings will present the following information 
where appropriate: absolute risks for treatment and control, estimates of relative risk, and a 
ranking of the quality of the evidence based on the risk of bias, directness, heterogeneity, 
precision, and risk of publication bias of the review results. The outcomes reported in the 
Summary of Findings will address the incidence of pre-eclampsia. 
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Appendix I: Search strategy 
Database: Ovid MEDLINE (R) [1946 to May Week 2 2020], searched 16 May 2020.  
Search  Query Results 
#1 (Nitrate OR "nitric oxide" OR OR arginine OR citrulline OR OR "isosorbide 
mononitrate" OR "isosorbide dinitrate" OR "glyceryl trinitrate" OR "sodium 
nitroprusside" OR "nitrosoglutathione" OR "pentaerythritol tetranitrate").mp 
298,161 
#2 (Pre*eclampsia OR "Chronic hypertension" OR "pregnancy-induced 
hypertension" OR "impaired utero-placental perfusion").mp 
22,660 
#3 "Asymmetric dimethylarginine".mp 2,417 
#4 (Endothelial growth factor OR placental growth factor).tw,kw. 52,650 
#5 Doppler test.mp 101 
#6 #3 OR #4 OR #5 55,142 
#7 Pregnancy.mp 91,5614 
#8 "high*risk pregnancy".mp 3 
#9 primigravidae.mp 1,128 
#10 nullipar*.mp 11,013 
#11 #7 OR #8 OR #9 OR #10 918,673 
#12 #2 OR #6 OR #11 972,128 
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#13 #1 AND #12 11,393 
#14 clinical trial* OR "Random* controlled trial*" OR rct* 1,307,294 
#15 #13 AND #14 744 
No language limits, No limits on date, No limit on age  
 
